Racial and Ethnic Representation in Dementia Clinical Trials Registered on ClinicalTrials.gov in the United States, United Kingdom, and Canada
International Journal of Geriatric Psychiatry · 2026-05 · 41 (5)
DOI: 10.1002/gps.70211 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Geriatric Psychiatry, online erschienen am 09.05.2026. Verfasst von Daniel Kramarczyk und 6 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK. Hauptthemen laut MEDLINE: Clinical Trials as Topic, Dementia, Ethnicity, Patient Selection. Die Arbeit nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Institute for Health and Care Research HealthTech Research Center in Brain Health..
Themen: Demenz
Abstract (Originalsprache)
Objective
To evaluate racial and ethnic representation and temporal trends in phase II–IV dementia clinical trials conducted in the United States, United Kingdom, and Canada.
Methods
We interrogated ClinicalTrials.gov for interventional dementia and Alzheimer's disease (AD) trials completed since 2000. Data on age, gender, and ethnicity were extracted from 163 eligible trials. Representation was compared across two time periods (2000–2015 and 2016–2019) to assess progress in diversity.
Results
Of the 163 trials, 58.9% ( n = 96) reported ethnicity data. Among the 12,900 participant records in these trials, 80.6% were Caucasian. Since 2016, despite improved reporting standards (100% of recent trials reported ethnicity), actual diversity declined: Asian participant representation dropped from 4.9% to 1.2%, and Hispanic/Latino representation fell from 2.2% to 0.7%. No ethnic minority group showed an increase in participation over the study period.
Conclusions
Diverse ethnic groups remain significantly underrepresented in dementia clinical trials, with diversity metrics stagnating or declining over the last decade. Greater inclusivity in trial design and recruitment is urgently required to ensure that emerging dementia treatments are safe and effective for all populations.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK.
- University of Exeter Medical School, University of Exeter, Exeter, UK.
- University of Nevada, Las Vegas, Nevada, USA.
ORCID-Profile: Daniel Kramarczyk, Zunera Khan
Förderung
- National Institute for Health and Care Research HealthTech Research Center in Brain Health.
Zitieren
APA
Kramarczyk, D., Ballard, C., Corbett, A., Da Silva, M. V., Mcleish, K. I., Cummings, J., & Khan, Z. (2026). Racial and Ethnic Representation in Dementia Clinical Trials Registered on ClinicalTrials.gov in the United States, United Kingdom, and Canada. International Journal of Geriatric Psychiatry, 41(5). https://doi.org/10.1002/gps.70211
Vancouver
Kramarczyk D, Ballard C, Corbett A, Da Silva MV, Mcleish KI, Cummings J, et al. Racial and Ethnic Representation in Dementia Clinical Trials Registered on ClinicalTrials.gov in the United States, United Kingdom, and Canada. International Journal of Geriatric Psychiatry. 2026;41(5). doi:10.1002/gps.70211
BibTeX
@article{Kramarczyk2026,
author = {Kramarczyk, Daniel and Ballard, Clive and Corbett, Anne and Da Silva, Miguel Vasconcelos and Mcleish, Kamara Israel- and Cummings, Jeffrey and Khan, Zunera},
title = {Racial and Ethnic Representation in Dementia Clinical Trials Registered on ClinicalTrials.gov in the United States, United Kingdom, and Canada},
journal = {International Journal of Geriatric Psychiatry},
year = {2026},
volume = {41},
number = {5},
doi = {10.1002/gps.70211}
}
EUVIMED